-
Summary: The U.S. reports multiple incidents of animal infections with new crowns
Time of Update: 2021-09-28
S. reports multiple cases of animal infections with COVID-19 Xinhua News Agency reporter Deng Xianlai Xu Jianmei The Smithsonian National Zoo in Washington, DC, said on the 17th that six lions and three tigers in the park had tested positive for the new crown virus and that these animals were being treated .
-
The second domestic one!
Time of Update: 2021-09-20
Source: State Drug AdministrationRuijio Lun Sai injection (formerly known as: Rui Ji Lun Sai injection) is an anti-CD19 CAR-T product developed by WuXi Juno, which is intended to treat various B cell malignant tumors.
-
Top 20 pharmaceutical companies in cash flow!
Time of Update: 2021-09-20
One believes that compared with other industries, the R&D investment of pharmaceutical companies is much more important than cash flow.
-
More than 10 new drugs have been approved for clinical use!
Time of Update: 2021-09-20
This time, HMPL-453 was approved for clinical use in China, and the proposed development indications are: combined chemotherapy or anti-PD-1 monoclonal antibody for patients with advanced solid tumors .
-
Can the Insulin Collective Harvester and Tonghua Dongbao's leader stabilize the three multinational giants? How to break the situation?
Time of Update: 2021-09-20
The domestic insulin market is mainly controlled by 3 multinational pharmaceutical companies Novo Nordisk, Sanofi, Eli Lilly, Tonghua Dongbao, Ganli Pharmaceutical, Zhuhai Federation, Jiangsu Wanbang and other companies .
-
Courtesy View Good Targeted Protein Degradation Platform Receives Another US$70 Million In Help
Time of Update: 2021-09-20
The company's goal is to use the LYTAC technology platform to develop a variety of treatment methods for a series of treatment fields and diseases against cell surface receptors and secreted proteins that are difficult to target by traditional small molecule inhibitors .
Retrieved September 9, 2021, from https:// 2294155/0/en/Lycia-Therapeutics-Announces-70-Million-Series-B-Financing-Led-by-Redmile-Group-with-Participation-from-Founding-Investor-Versant-Ventures.
-
Business pain, business pain, medical insurance pain!
Time of Update: 2021-09-20
Author: Shandong FengqingWhen it comes to mass procurement of medicines, it is now at a stage where companies are suffering, business is suffering, and the medical insurance bureau is distressed .
-
Pfizer JAK1 inhibitor approved in the UK to treat atopic dermatitis
Time of Update: 2021-09-20
Pfizer (Pfizer) announced today that the British Medicines and Health Products Administration (MHRA) has approved the oral JAK1 inhibitor Cibinqo (abrocitinib) to be marketed in the UK for the treatment of moderate to severe disease in adults and adolescents over 12 years old who are suitable for systemic therapy.
-
Northeast Pharmaceutical will be acquired by a comprehensive tender offer
Time of Update: 2021-09-20
On August 23, Northeast Pharmaceutical issued an announcement stating that Fangda Steel had acquired all shares of Northeast Pharmaceutical held by Dongyao Group and Shengjing Financial Holding Group and triggered the tender offer .
-
Tohoku Pharmaceutical: Dapoxetine hydrochloride, the raw material, passed CDE approval
Time of Update: 2021-09-20
On August 26, Northeast Pharmaceutical issued an announcement stating that the company had recently inquired and learned on the platform of the “Registration Information Disclosure of APIs, Pharmaceut
-
For follicular lymphoma, Hutchison Whampoa HMPL-689 capsules are planned to be included in breakthrough treatment varieties
Time of Update: 2021-09-20
In preclinical pharmacokinetic studies, it was confirmed that HMPL-689 has good oral absorption, moderate tissue distribution and low clearance rate .
Preclinical studies also expect that HMPL-689 has a low risk of drug accumulation and drug-drug interactions, and is active at the level of whole blood .
-
Youzhiyou Biotech completes B-2 round of financing for the clinical development of M701 and M802
Time of Update: 2021-09-20
According to the information on the official website of Youzhiyou Biology, M701 is a recombinant anti-EpCAM and CD3 human-mouse chimeric bispecific antibody product for injection.
In addition, Youzhiyou Bio also has a recombinant anti-CD38 and CD3 bispecific antibody for injection (R&D code: Y150) which has also been approved for clinical use in 2021 .
-
The fifth batch of Guocai Shanghai requires preparations for admission to the hospital in advance!
Time of Update: 2021-09-20
On August 30, the latest notice of the Shanghai Municipal Pharmaceutical Centralized Bidding and Purchasing Affairs Management Office mentioned that the fifth batch of 61 nationally selected drugs is expected to be officially implemented in Shanghai in late October, requiring preparations for admission to the hospital in advance .
-
The two companies jointly issued a notice on doing a good job in the examination and approval and supervision of radiopharmaceutical production and operation enterprises
Time of Update: 2021-09-20
According to the opinions of the provincial administrative department of national defense science, technology and industry, if the conditions are met, it shall be approved, and the local provincial drug supervision and administration department shall issue a radiopharmaceutical business license; if the conditions are not met, a written decision of disapproval shall be made and the reasons shall be explained .
-
Approximately US$1.9 billion won the first approved ROCK2 inhibitor Sanofi to expand its transplantation drug pipeline
Time of Update: 2021-09-20
The acquisition will add Kadmon's small molecule therapy Rezurock (belumosudil) to its transplant portfolio .
In July 2021, the US FDA approved the company's Rezurock for the treatment of chronic graft-versus-host disease (cGVHD) children (12 years and older) and adult patients.
-
The pharmaceutical retail industry on the eve of the big change
Time of Update: 2021-09-20
Secondly, with the reform of medical insurance and hospitals, without large-scale subsidies to medical institutions, it is impossible for the pharmaceutical retail market to rely on prescription drugs to scale up .
-
Sinopharm Hyundai Ceftriaxone Sodium for Injection Obtained Marketing License in Malta
Time of Update: 2021-09-20
On September 3, Sinopharm Hyundai issued an announcement stating that DALI PharmaGmbH, a wholly-owned subsidiary established by its holding subsidiary Zhijun Pharmaceuticals in Germany, received the approval of the Malta Pharmaceutical Regulatory Authority to issue ceftriaxone sodium for injection (250mg/500mg/ 1g) Marketing authorization .
Its indication is that ceftriaxone sodium is a long-acting, broad-spectrum third-generation cephalosporin antibiotic.
-
The Health Commission urgently notified and strictly investigated unreasonable out-of-hospital prescriptions!
Time of Update: 2021-09-20
According to Dami’s understanding, the Chongqing Municipal Health Commission has issued the "Emergency Notice on Further Strengthening the Management of Clinical Rational Drug Use in Medical Institutions".
-
Tianyao Amino Acid (15) Peritoneal Dialysis Solution Obtained Drug Registration Certificate
Time of Update: 2021-09-20
On August 27, Tianyao issued an announcement stating that its subsidiary Jinyao Pharmaceutical had recently received the "Drug Registration Certificate" for amino acid (15) peritoneal dialysate approved and issued by the State Food and Drug Administration .
-
About Guocai!
Time of Update: 2021-09-20
The United Procurement Office stated that since the implementation of the results of the centralized procurement of coronary stents organized by the state, the overall progress has been stable, the price has dropped significantly, the supply of selected products is sufficient, and the people have clearly benefited .
